Collagen Medical was founded in 2010 by Peter Caravan, Ph.D. from Harvard University and Massachusetts General Hospital (MGH) and A. Gregory Sorensen, MD, President and CEO, Siemens Healthcare, North America (Formerly Director of the A.A. Martinos Center for Biomedical Imaging at MGH).  The company purchased the collagen targeting intellectual property that the founders discovered and developed while employed at EPIX Pharmaceuticals, including an issued patent on composition of matter and use.  Collagen Medical’s patented technology has applications that extend to diagnosis of fibrotic disease in other tissues (kidney and lung) and have significant potential for enabling novel ECM targeted therapies to treat fibrosis and associated medical conditions.  The company’s executive team and scientific advisory board are leaders in MRI, contrast agent chemistry and biophysics, medical and cardiac imaging, cardiology, and fibrosis. 

Management team

Peter Caravan, PhD:
Founder. Dr. Caravan is Assistant Professor of Radiology at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS). MGH/HMS. He was formerly Principal Scientist at Epix Pharmaceuticals.  Dr. Caravan is an expert in imaging probe development and applications.  He is the Principal Investigator on four NIH R01 grants related to PET and MRI probe development.  He has published over 80 peer-reviewed papers on probe development and has 16 issued or pending US patents.  Dr. Caravan is co-inventor of the core company gadolinium chelate and targeting technologies.   

Gregory Sorensen, MD: Founder. Dr. Sorensen is President and CEO of Siemens Healthcare North America.  He was formerly Professor of Radiology at MGH/HMS, Co-Director of the A.A. Martinos Center for Biomedical Imaging at MGH, as well as a visiting professor of neuroradiology at Oxford University. Dr. Sorensen brings expertise in business development, clinical care, clinical trials, and translational research.

Valerie Humblet, PhD: Head of Research and Development. Dr. Humblet holds a PhD in Chemistry from the University of Liege and developed imaging probes as a post-doctoral fellow in the lab of Dr. John Frangioni at BIDMC/HMS.  She was Imaging Liaison for the Harvard Catalyst program. Dr. Humblet overseas all research operations at the company.